BJMO - volume 10, issue 7, november 2016
S. Elsen PhD, E. Lerut MD, PhD, B. Van Cleynenbreugel MD, PhD, F. Van der Aa MD, PhD, H. Van Poppel MD, PhD, P.A. de Witte PhD
The diagnosis of non-muscle-invasive bladder cancer using the standard white-light cystoscopy technique is not optimal and leads to underdiagnosis of some of the tumours. Therefore, in this thesis, the use of Evans blue dye as a diagnostic tool to aid bladder cancer detection during white-light cystoscopy was investigated using a rat orthotopic bladder cancer model. The results show that Evans blue might have great potential to assist detection of bladder cancer in a clinical setting.
(BELG J MED ONCOL 2016;10(7):281–284)
Read moreBJMO - volume 10, issue 6, september 2016
H. Van Poppel MD, PhD
The 31st European Association of Urology Annual Congress took place in March 2016 in Munich. In prostate cancer the early use of chemotherapy in addition to androgen deprivation therapy in men with primary metastatic disease is a clinical practice changing concept that needs implementation through collaboration between urologists and medical oncologists.
The role of MRI and fusion biopsies in early detection, diagnosis and active surveillance strategies is becoming more and more important. In bladder cancer, non-urothelial tumour types got a lot of attention and specific treatment strategies were presented. Furthermore, immunological treatment came forward to perhaps replace chemotherapy in the management of advanced urothelial bladder cancer.
(BELG J MED ONCOL 2016;10(6):228–231)
Read moreBJMO - volume 10, issue 4, july 2016
H. Van Poppel MD, PhD
The 13th meeting of the EAU Section of Oncological Urology took place in Warsaw in January 2016. The most important newcomers were the checkpoint inhibitors in metastatic renal cell carcinoma and in bladder cancer. In prostate cancer, early administration of docetaxel in newly diagnosed metastatic prostate cancer was the major practice changing news, next to whole exome and transcriptome sequencing that will become important
(BELG J MED ONCOL 2016;10(4):143–146)
Read moreBJMO - volume 9, issue 7, december 2015
H. Van Den Bossche MD, R. Kokx MD, M. Albersen MD, PhD, C. Assenmacher MD, H. Van Poppel MD, PhD, S. Joniau MD, PhD
High-intensity focused ultrasound has been used as an alternative treatment for prostate cancer, as both primary or salvage treatment. It is considered a minimally invasive treatment modality. We recently needed to care for two patients with severe osteomyelitis of the pubic bone as a result of a prostatopubic fistula, after they underwent salvage high-intensity focused ultrasound treatment post-radiotherapy.
(BELG J MED ONCOL 2015;9(7):290–95)
Read moreBJMO - volume 9, issue 5, september 2015
D. Mortier MD, H. Van Poppel MD, PhD
To present a comparison between the recommendations for early detection of prostate cancer in men without evidence of prostate cancer related symptoms, as proposed by the European Association of Urology and the American Urological Association. Prostate-specific antigen screening for prostate cancer has been and still is one of the most controversial issues in medicine. Recent guideline statements and recommendations have led to further confusion and controversy regarding the use of prostate-specific antigen testing for the early detection of prostate cancer. In this text we try to summarise the different points of view of both societies and the evidence they are based upon.
(BELG J MED ONCOL 2015;9(5):179–82)
Read moreBJMO - volume 8, issue 5, december 2014
J. Gysen MD, H. Van Poppel MD, PhD
We present a condensed version of the ESMO clinical practice guidelines on penile cancer.1
Penile cancer is an uncommon but ominous disease. In the last few years there has been a shift towards penile-preserving techniques, because besides local control, an important aim of surgery is to preserve the functionality and sexual function of the penis. This has an important impact on the patient’s self-esteem, quality of life and general mental health. Despite the rarity of the disease we gradually achieve more insight in the proper staging and treatment of this malignancy.
(BELG J MED ONCOL 2014;8(5):213–6)
Read moreBJMO - volume 8, issue 5, december 2014
A. Alberts MD, S. Joniau MD, PhD, H. Van Poppel MD, PhD
A solitary pulmonary metastasis of prostate cancer is not considered a surgical lesion. However, growing evidence supports that highly selected patients could benefit from metastasectomy of a solitary pulmonary metastasis. We present an exceptional case of resection of two metachronous pulmonary metastases of prostate cancer after previous radical prostatectomy, resulting in nearly undetectable prostate-specific antigen (0.04 ng/ml).
(BELG J MED ONCOL 2014;8(5):217–9)
Read more
Top
